Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Redhill Biophrma ADR (RDHL)

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,390
  • Shares Outstanding, K 21,936
  • Annual Sales, $ 8,360 K
  • Annual Income, $ -38,820 K
  • 60-Month Beta 1.60
  • Price/Sales 18.00
  • Price/Cash Flow N/A
  • Price/Book 3.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.32
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.33
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.39 +0.44%
on 06/25/19
7.70 -16.65%
on 05/28/19
-1.40 (-17.87%)
since 05/24/19
3-Month
6.39 +0.44%
on 06/25/19
8.94 -28.21%
on 04/02/19
-2.22 (-25.72%)
since 03/26/19
52-Week
5.13 +25.11%
on 12/24/18
11.49 -44.14%
on 07/16/18
-1.57 (-19.67%)
since 06/26/18

Most Recent Stories

More News
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections

-- The new patent expands the robust patent portfolio covering RHB-104 and RHB-204

RDHL : 6.42 (+0.28%)
RedHill Biopharma Submits New Drug Application for Talicia(R) for H. pylori Infection

EQNX::TICKER_START (NasdaqGM:RDHL),(TASE:RDHL.TA), EQNX::TICKER_END

RDHL : 6.42 (+0.28%)
RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights

Key Highlights and Upcoming Milestones:

RDHL : 6.42 (+0.28%)
RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced...

RDHL : 6.42 (+0.28%)
Report: Exploring Fundamental Drivers Behind Abercrombie & Fitch, VALE S.A, Mallinckrodt public limited company, Veritone, Tecnoglass, and Redhill Biopharma -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Abercrombie & Fitch Company (NYSE:ANF),...

RDHL : 6.42 (+0.28%)
ANF : 15.74 (+2.47%)
MNK : 8.40 (unch)
VALE : 13.43 (+0.75%)
TGLS : 6.25 (-0.32%)
VERI : 8.21 (+3.79%)
RedHill Biopharma to Present at Three Conferences in April

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced...

RDHL : 6.42 (+0.28%)
RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced...

RDHL : 6.42 (+0.28%)
RedHill Biopharma to Present at the 31st Annual ROTH Conference

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced...

RDHL : 6.42 (+0.28%)
RedHill Biopharma Announces New European and Japanese Patents for Talicia(R)

-- The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034

RDHL : 6.42 (+0.28%)
RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights

RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today reported...

RDHL : 6.42 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade RDHL with:

Business Summary

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers...

See More

Key Turning Points

2nd Resistance Point 7.06
1st Resistance Point 6.73
Last Price 6.42
1st Support Level 6.23
2nd Support Level 6.06

See More

52-Week High 11.49
Fibonacci 61.8% 9.06
Fibonacci 50% 8.31
Fibonacci 38.2% 7.56
Last Price 6.42
52-Week Low 5.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar